Two large, independent pharmaceutical companies; worldwide locations
Pre-close to the merger of two global pharmaceutical companies, both parties were exploring ways to identify synergies among their teams through either the exchange of divisions or joint venture arrangements.
Exchanging assets or setting up a joint venture while remaining compliant with pharmaceutical regulations was a top priority. Both companies needed pharmaceutical merger experience and technology expertise to manage the exploration, while not disrupting day-to-day operations.
Bringing LABUR in pre-close allowed for synergies to be identified early. Rules of engagement were established to gather requirements from both companies separately. Integration steps were established, as well as cross-functional teams. Diligent data gathering and analysis in audit, compliance, reporting, and technology systems was completed to assess the merger in core areas of operation.
LABUR worked to gather business and technology requirements to assess and plan for operations post-merger, including configuring applications to properly route for data exchanges. A new organizational structure was outlined, as well as budget and timelines for delivery, including user support through go-live.
The pre-close foundational support LABUR provided identified synergy opportunities on multiple levels of business operations for both pharmaceutical companies. Day-to-day activities were not disrupted, and an efficient transformation and alignment of divisions was completed. The efficiency of this transaction as streamlined by LABUR allowed the two companies to jointly identify a total global leadership footprint and organization chart.
Our expertise spans industries and crosses functionalities within the enterprise.
The breadth of our experience runs deep, but our approach is targeted. We apply relevant best practices and tactical experience without compromising the unique circumstances of each client and each engagement.